Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 184 participants.

Also called NCT02135029

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 184 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02135029
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02135029. Randomized; quadruple masking; primary purpose treatment. Start 2014-06 (actual); primary completion 2015-11 (actual). Results posted on 2017-12-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
Acronym
SPIRE-SI
Condition
Hyperlipidemia
Intervention (Drug)
Bococizumab (PF-04950615;RN316)
Intervention (Drug)
Atorvastatin
Intervention (Other)
Placebo for Bococizumab (PF-04950615;RN316)
Intervention (Other)
Placebo for atorvastatin
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct02135029
Content hash
ea207b443b81a6dc9b669f16bc38edbffeef751ccd673597f3c28642eb62595c